{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:06:50Z","timestamp":1740107210471,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00405-019-05665-5","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T10:10:57Z","timestamp":1570097457000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results"],"prefix":"10.1007","volume":"277","author":[{"given":"Marius","family":"Breheret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Lubgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Traxdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kitzsteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Kuwert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Iro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-6003","authenticated-orcid":false,"given":"Sabine","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"5665_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","volume":"118","author":"W Budach","year":"2016","unstructured":"Budach W, B\u00f6lke E, Kammers K et al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol 118:238\u2013243","journal-title":"Radiother Oncol"},{"key":"5665_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2591","author":"L Geoffrois","year":"2018","unstructured":"Geoffrois L, Martin L, De Raucourt D et al (2018) Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007\u201302 phase III randomized trial. J Clin Oncol. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.76.2591\n\n(In press)","journal-title":"J Clin Oncol"},{"key":"5665_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E","volume":"54","author":"JF Ensley","year":"1984","unstructured":"Ensley JF, Jacobs JR, Weaver A et al (1984) Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811\u2013814","journal-title":"Cancer"},{"key":"5665_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91\u201311: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845\u2013852","journal-title":"J Clin Oncol"},{"key":"5665_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695\u20131704","journal-title":"N Engl J Med"},{"key":"5665_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","volume":"29","author":"A Dietz","year":"2018","unstructured":"Dietz A, Wichmann G, Kuhnt T et al (2018) Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 29:2105\u20132114","journal-title":"Ann Oncol"},{"key":"5665_CR7","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.2007.12.7597","volume":"26","author":"FP Worden","year":"2008","unstructured":"Worden FP, Kumar B, Lee JS et al (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138\u20133146","journal-title":"J Clin Oncol"},{"key":"5665_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","volume":"24","author":"S Urba","year":"2006","unstructured":"Urba S, Wolf G, Eisbruch A et al (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24:593\u2013598","journal-title":"J Clin Oncol"},{"key":"5665_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00066-010-2178-2","volume":"187","author":"S Semrau","year":"2011","unstructured":"Semrau S, Waldfahrer F, Lell M et al (2011) Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol 187:15\u201322","journal-title":"Strahlenther Onkol"},{"key":"5665_CR10","doi-asserted-by":"publisher","first-page":"e4450","DOI":"10.1097\/MD.0000000000004450","volume":"95","author":"RF Dos Anjos","year":"2016","unstructured":"Dos Anjos RF, Dos Anjos DA, Vieira DL et al (2016) Effectiveness of FDG-PET\/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: a systematic review. Medicine (Baltimore) 95:e4450. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000004450","journal-title":"Medicine (Baltimore)"},{"key":"5665_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1385\/MO:23:3:325","volume":"23","author":"T Kuhnt","year":"2006","unstructured":"Kuhnt T, Becker A, Bloching M et al (2006) Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors. Med Oncol 23:325\u2013333","journal-title":"Med Oncol"},{"key":"5665_CR12","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1093\/annonc\/mds065","volume":"23","author":"JL Lefebvre","year":"2012","unstructured":"Lefebvre JL, Andry G, Chevalier D et al (2012) Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23:2708\u20132714","journal-title":"Ann Oncol"},{"key":"5665_CR13","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EE Cohen","year":"2014","unstructured":"Cohen EE, Karrison TG, Kocherginsky M et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32:2735\u20132743","journal-title":"J Clin Oncol"},{"key":"5665_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O'Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257\u2013264","journal-title":"Lancet Oncol"},{"key":"5665_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","volume":"31","author":"JL Lefebvre","year":"2013","unstructured":"Lefebvre JL, Pointreau Y, Rolland F et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 31:853\u2013859","journal-title":"J Clin Oncol"},{"key":"5665_CR16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00066-018-1360-9","volume":"194","author":"J Kufeldt","year":"2018","unstructured":"Kufeldt J, Viehrig M, Schweikert D et al (2018) Treatment of malnutrition decreases complication rates and shortens the length of hospital stays in a radiation oncology department. Strahlenther Onkol 194:1049\u20131059","journal-title":"Strahlenther Onkol"},{"key":"5665_CR17","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s00066-018-1328-9","volume":"194","author":"S Ursino","year":"2018","unstructured":"Ursino S, Cocuzza P, Seccia V et al (2018) Pattern of dysphagia after swallowing-sparing intensity-modulated radiotherapy (IMRT) of head and neck cancers: results of a mono-institutional prospective study. Strahlenther Onkol 194:1114\u20131123","journal-title":"Strahlenther Onkol"},{"key":"5665_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp007","volume":"101","author":"Y Pointreau","year":"2009","unstructured":"Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498\u2013506","journal-title":"J Natl Cancer Inst"},{"key":"5665_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-019-01451-8","author":"A Modesto","year":"2019","unstructured":"Modesto A, Galissier T, Lusque A et al (2019) Definitive radiochemotherapy or initial surgery for oropharyngeal cancer: to what extent can p16 expression be used in the decision process? Strahlenther Onkol. \nhttps:\/\/doi.org\/10.1007\/s00066-019-01451-8","journal-title":"Strahlenther Onkol"},{"issue":"15_suppl","key":"5665_CR20","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1200\/JCO.2017.35.15_suppl.6016","volume":"35","author":"R Fietkau","year":"2017","unstructured":"Fietkau R, Iro H, Hecht M et al (2017) Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel\/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil\/cisplatinum. J Clin Oncol 35(15_suppl):6016\u20136016","journal-title":"J Clin Onco"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-019-05665-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-019-05665-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-019-05665-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:01:47Z","timestamp":1601596907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-019-05665-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5665"],"URL":"https:\/\/doi.org\/10.1007\/s00405-019-05665-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"type":"print","value":"0937-4477"},{"type":"electronic","value":"1434-4726"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Torsten Kuwert receives honoraria from Siemens Healthineers for lectures. The Erlangen Clinic of Nuclear Medicine has a research cooperation with that company on the field of SPECT\/CT. Markus Hecht reports advisory board services for Merck Serono, MSD and BMS, travel support from Merck Serono, MSD and TEVA and research funding from AstraZeneca, MSD and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all individual participants included in the study. Due to using the established standard protocol in our departments and retrospective method, formal consent for this type of study is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}